MOM

Miraculins Inc. (TSX VENTURE:MOM) ("Miraculins" or the "Company"), a medical
diagnostic company focused on acquiring, developing and commercializing
diagnostic tests and risk assessment technologies for unmet clinical needs,
today announces that the Company has finalized the major terms of a definitive
agreement (the "Agreement"), that would see the Scout DS(R) Diabetes Screening
Test distributed exclusively in China by Cachet Pharmaceutical Co., Ltd.
("Cachet"). These terms are substantially similar to those outlined in the
Company's term sheet announcement made January 31, 2014, and include the
placement of an initial order for Scout DS(R) devices valued at $15 Million USD
on the signing of the Agreement, to be activated upon Chinese Food and Drug
Administration regulatory clearance.  


"I am pleased to confirm that we have now finalized the major aspects of the
Agreement for the exclusive distribution of Scout DS(R) in China by Cachet, and
that the signatory parties have advised of their intentions to proceed with the
execution of the Agreement within the next 30 days," said Christopher J. Moreau,
President and CEO of Miraculins Inc.  


Coinciding with the anticipated timing of the signing of the Agreement, a
delegation from Cachet's senior management team in Beijing is scheduled to
arrive in Canada in mid-July and will be conducting next stage distribution
planning sessions with Miraculins. The Chinese delegation will also be visiting
the production facility in the U.S. where the Scout DS(R) devices will be
manufactured, during their trip. 


The key deal terms will be announced once the Agreement has been executed. The
execution of the Agreement remains subject to all final corporate approvals of
the parties. There is no assurance that the parties will enter into the final
Agreement. 


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 


Caution Regarding Forward-Looking Information 

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements include statements regarding the settlement of agreement terms, the
execution of the final Agreement, the placement of the initial order, and the
impact of the final Agreement on the Company. These forward-looking statements
relate to, among other things, our objectives, goals, targets, strategies,
intentions, plans, beliefs, estimates and outlook, including, without
limitation, our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate," "expect,"
"intend," "plan," "will," "may" and other similar expressions. In addition, any
statements that refer to expectations, projections or other characterizations of
future events or circumstances are forward-looking statements.  


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events. 


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statements. 


Scout DS(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2014. 

FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

Miraculins Inc. (TSXV:MOM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Miraculins Inc. (TSXV:MOM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024